The economic burden of hospitalization for cardiac arrhythmias requiring implantable cardioverter-defibrillator and radiofrequency ablation among adult Filipinos—Its clinical and equity implications and budget impact analysis of proposed revised PhilHealth case rates for cardioverter-defibrillator implantation and radiofrequency ablation
- Author:
Bernadette A. Tumanan-Mendoza
1
,
2
;
Victor L. Mendoza
3
,
4
;
Eden A. Gabriel
5
,
6
;
Giselle G. Gervacio
1
,
5
,
7
;
Erdie C. Fadreguilan
5
;
Michael-Joseph F. Agbayani
1
,
5
,
7
;
Gladys Ruth S. David
5
,
6
;
Luigi Pierre S. Segundo
8
;
Carlos E. De Las Llagas
9
;
Magdalena J. Lagamayo
10
;
Felix Eduardo R. Punzalan
1
,
7
;
April Ann A. Bermudez-delos Santos
1
;
Noemi S. Pestaño
1
Author Information
- Publication Type:Journal Article
- Keywords: PhilHealth
- MeSH: Radiofrequency Ablation; Defibrillators, Implantable
- From: Philippine Journal of Cardiology 2021;49(1):30-38
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND:Radiofrequency ablation (RFA) is the recommended treatment of choice for supraventricular tachycardia (SVT), whereas implantable cardioverter-defibrillator (ICD) is recommended for patients at high risk for sudden death due to ventricular tachycardia/fibrillation. Radiofrequency ablation has been proven to improve the quality of life of patients with SVT, whereas an ICD has been shown to reduce mortality among patients at risk for sudden cardiac death. Both procedures are expensive and usually beyond the reach of the average Filipino patient.
OBJECTIVES:The objectives are to (1) determine the cost of hospitalization for cardiac arrhythmias that require RFA and cardioverter-defibrillator implantation in the Philippines, (2) propose revised Philippine Health Insurance Corporation (PhilHealth) benefit packages for both procedures, and (3) determine the budget impact of the proposed revised packages.
METHODS:Hospitalization costs were obtained for both RFA and cardioverter-defibrillator implantation from two government tertiary care hospitals. A range of hospitalization costs involving possible lower and higher cost scenarios was estimated. Based on these estimates and the yearly number of arrhythmias that require these procedures, revised benefit packages for both RFA and cardioverter-defibrillator implantation were proposed to PhilHealth. The budget impact analysis for the first 3 and 5 years of implementation of these revised packages was subsequently calculated.
RESULTS:The estimated hospitalization costs for RFA ranged from Philippine pesos (PHP) 248,485 to 310,480, whereas for cardioverter-defibrillator implantation, the costs ranged from PHP 509,122 to 581,940. These amounts are greatly disparate from the present PhilHealth coverages, which are PHP 9700 and 18,000 for RFA and cardioverter-defibrillator implantation, respectively. Based on these hospitalization costs, the proposed RFA benefit package is PHP 275,000 to 310,000, whereas for an ICD benefit package, PHP 513,000 to 576,000 is proposed. The incremental cost of more than PHP 300 million for RFA and more than PHP 700 million for an ICD is distributed for the next 3 or 5 years of implementation for these benefit packages, respectively.
CONCLUSION:The present PhilHealth case rates for both RFA and cardioverter-defibrillator implantation are greatly underestimated, which probably is the reason for their underutilization. There is a need to revise these case rates with due consideration of their actual hospitalization costs to lessen inequity in accessing these procedures. - Full text:202410210827388655730_PJC Jan Jun 2021.pdf
